EUCTR2018-002155-15-ES进行中（未招募）1 期
A randomized, open label, phase II trial of Anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation
Grupo Español de Investigación en Cáncer de Ovario (GEICO)0 个研究点目标入组 132 人开始时间: 2019年5月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Signed informed consent before any study-specific procedure.
- •2. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of = 1.
- •3. Participant must be a female = 18 years of age.
- •4. Life expectancy =3 months.
- •5. Participant must have biopsy-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix.
- •6. Patients must have archival tumor tissue available that is formalin-fixed and paraffin embedded.
- •7. At diagnosis:
- •FIGO stages IB2, IIA2, IIB with pelvic lymph node involvement.
- •FIGO stages IIIA, IIIB, IVA.
- •Any FIGO stage with para-aortic lymph node involvement
- •8. Subjects must have received combination chemotherapy and radiotherapy (CCRT) with curative intent. Patients must have received at least 4 doses of weekly cisplatin.
- •9. Patients must had achieved a partial (PR) or a complete response (CR) after concurrent chemo-radiation therapy (CCRT).
- •10. Patients must have completed definitive treatment, namely chemo-radiation, up to 12 weeks prior to sign the Informed Consent form.
- •11. Toxicities resulting from chemo-radiation must resolve to = Grade 1 prior to randomization.
- •12.Participant must have adequate organ function, defined as follows:
- •- Absolute neutrophil count = 1,500/µL
- •- Platelets = 100,000/µL
- •- Hemoglobin = 9 g/dL
- •- Serum creatinine = 1.5× upper limit of normal (ULN) or calculated creatinine clearance = 50 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN
- •- Total bilirubin = 1.5× ULN OR direct bilirubin = 1× ULN
- •- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5× ULN
- •- International normalized ratio (INR) or prothrombin time (PT) =1.5× ULN. Activated partial thromboplastin time (aPTT) =1.5× ULN
- •13. Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
- •14. Negative Test Results for Hepatitis
- •15. Female participant has a negative serum pregnancy test within 72 hours prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 150 days after the last dose of study treatment, or is of nonchildbearing potential.
- •16. Participant must agree to not breastfeed during the study or for 150 days after the last dose of study treatment
- •17. Male partners must agree to use an adequate method of contraception starting with the first dose of study treatment through 150 days after the last dose of study treatment.
- •18.Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 32
排除标准
- •1. Histological types other than in inclusion criteria, like sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial cancers
- •2. FIGO Stage IVB
- •3. Subjects who have undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy.
- •4. Has not achieved at least a partial response by RECIST v1.1 after completion of CCRT administered with curative intent.
- •5. Patients previously treated with chemotherapy except when used concurrently with radiation therapy.
- •6. Prior treatment with any anti-VEGF drug, including bevacizumab, CD137 agonists or immune checkpoint blockade therapies, anti-PD1, or anti-PDL1 therapeutic antibodies or anti-CTLA 4.
- •7. Patients with a concomitant malignancy other than non-melanoma skin cancer.
- •8. History of autoimmune disease
- •9. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
- •10. History of interstitial lung disease.
- •11. Active tuberculosis.
- •12. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1.
- •13. Administration of a live, attenuated vaccine within 14 days before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study.
- •14. Treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1.
- •15. Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1, Day 1.
- •16. Women that are breastfeeding or pregnant.
- •17. Demonstration of any other disease, neurological or metabolic dysfunction, found upon physical examination or laboratory tests involving a reasonable suspicion of the existence of a disease or condition that contraindicates the use of an experimental drug, or that involves an increased risk to the patient of treatment-related complications.
- •18. No medical or psychiatric illness that may impede the performance of a systemic or surgical treatment.
- •19. Participant must not be simultaneously enrolled in any interventional clinical trial.
- •20. Participant must not have had major surgery = 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects.
- •21. Participant must not have received investigational therapy = 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.
- •22. Participant has had radiation therapy encompassing >20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy.
- •23. Participant must not have a known hypersensitivity to TSR-042 components or excipients.
- •24. Participant must not have a serious, uncontrolled medical disorder or nonmalignant systemic disease.
- •25. Participant must not have known, symptomatic brain or leptomeningeal metastases.
- •26. Patient experienced = Grade 3 immune-related AE with prior
研究者
相似试验
进行中（未招募）
1 期
Trial of dostarlimab (TSR-042) for patients with high-risk locally advanced cervical cancer after chemo-radiatioMedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104Cervical cancerCTIS2023-510268-11-00Grupo Espanol De Investigacion En Cancer De Ovario132
尚未招募
2 期
Clinical trial of Methotrexate associated to Hydroxyurea versus placebo and Hydroxyurea in patients with sickle cell diseaseRBR-57qbjvCentro Infantil Boldrini
进行中（未招募）
1 期
Open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two different dose regimens of IPH 2101, a human monoclonal anti-KIR antibody, in patients with multiple myeloma in stable partial response after a first line therapyMultiple myelomaEUCTR2009-012136-33-FRInnate Pharma42
进行中（未招募）
1 期
A study of Iclusig (ponatinib), an oral kinase-inhibitor treatment administered, by standard dose or reduced doses, for patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) who no longer benefit from, or who have an abnormal gene (T315I positive) marker for resistance to other kinase-inhibitor treatments.EUCTR2014-001617-12-DETakeda Development Center Americas, Inc.276
撤回
不适用
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of DosesChronic Phase Chronic Myeloid Leukemiablood cancer10024324NL-OMON43934ARIAD Pharmaceuticals, Inc.5